Linical Co., Ltd. (JP:2183)
:2183
Want to see JP:2183 full AI Analyst Report?
2183 Stock Chart & Stats
¥293.00
-¥1.00(-0.28%)
At close: 4:00 PM EST
¥293.00
-¥1.00(-0.28%)
Day’s Range― - ―
52-Week Range¥251.00 - ¥363.00
Previous CloseN/A
Volume36.50K
Average Volume (3M)14.99K
Market Cap
¥5.67B
Enterprise Value¥2.89B
Total Cash (Recent Filing)¥5.53B
Total Debt (Recent Filing)¥2.22B
Price to Earnings (P/E)―
Beta0.65
Next Earnings
May 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.44%
Share Statistics
EPS (TTM)-27.61
Shares Outstanding24,740,000
10 Day Avg. Volume18,600
30 Day Avg. Volume14,993
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.00
Price to Sales (P/S)0.69
P/FCF Ratio12.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)29.7
Revenue Forecast (FY)¥13.00B
Bulls Say, Bears Say
Bulls Say
Durable CRO Business ModelLinical’s core fee‑for‑service CRO model is structurally aligned with the long lead times of drug development. Outsourcing trends and recurring, multi‑project contracts create durable revenue opportunities and client relationships that support predictable workload and contract renewals over months.
Balance Sheet LiquidityModerate leverage and a ~43% equity ratio, plus a negative net debt position, give Linical financial flexibility. This liquidity cushion supports funding project timing mismatches, payroll for specialized staff, and strategic investments without immediate external financing over the next several months.
Positive Operating Cash GenerationOperating cash generation is positive even with accounting losses, indicating effective billing and collections on sponsor contracts. Positive cash flow sustains working capital, funds clinical project execution, and reduces near-term refinancing risk while management works to restore profitability.
Bears Say
Declining Revenue And ProfitabilityA ~15% revenue decline and recent net losses signal weakening demand or lost contracts. For a services business with significant fixed costs and skilled headcount, sustained revenue erosion pressures utilization, limits reinvestment in capabilities, and threatens long‑term margin recovery.
Margin DeteriorationRelatively low gross margin and negative net margins indicate pricing pressure and cost inefficiencies. Continued margin deterioration constrains the firm’s ability to invest in specialized personnel, technology, and quality systems that differentiate CROs and support winning complex, higher‑margin studies.
Revenue Lumpyness / Pipeline DependenceLinical’s revenue is highly dependent on sponsor pipelines and discrete study awards, creating lumpy and timing‑sensitive cash flows. Inconsistent award cadence increases forecasting risk, utilization volatility, and the chance of underused staff or margin squeezes during troughs in project volume.
Linical Co., Ltd. News
2183 FAQ
What was Linical Co., Ltd.’s price range in the past 12 months?
Linical Co., Ltd. lowest stock price was ¥251.00 and its highest was ¥363.00 in the past 12 months.
What is Linical Co., Ltd.’s market cap?
Linical Co., Ltd.’s market cap is ¥5.67B.
When is Linical Co., Ltd.’s upcoming earnings report date?
Linical Co., Ltd.’s upcoming earnings report date is May 15, 2026 which is in 21 days.
How were Linical Co., Ltd.’s earnings last quarter?
Linical Co., Ltd. released its earnings results on Feb 13, 2026. The company reported -¥27.61 earnings per share for the quarter, missing the consensus estimate of N/A by -¥27.61.
Is Linical Co., Ltd. overvalued?
According to Wall Street analysts Linical Co., Ltd.’s price is currently Overvalued.
Does Linical Co., Ltd. pay dividends?
Linical Co., Ltd. pays a Annually dividend of ¥16 which represents an annual dividend yield of 5.44%. See more information on Linical Co., Ltd. dividends here
What is Linical Co., Ltd.’s EPS estimate?
Linical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Linical Co., Ltd. have?
Linical Co., Ltd. has 24,740,000 shares outstanding.
What happened to Linical Co., Ltd.’s price movement after its last earnings report?
Linical Co., Ltd. reported an EPS of -¥27.61 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.208%.
Which hedge fund is a major shareholder of Linical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:2183
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Linical Co., Ltd.
Linical Co., Ltd. provides drug development services primarily in the areas of oncology and central nervous system to pharmaceutical companies worldwide. The company offers drug development consulting services, such as market analysis of products in development, regulatory affairs consultation support, and licensing support. It also provides clinical research and development, and contract medical affairs services, including front-end services comprising project management, monitoring, quality control, vendor management, auditing, and clinical research secretariat; and back-end services, which include data management, bio statistical analysis, medical writing, pharmacovigilance, and medical management. The company was incorporated in 2005 and is headquartered in Osaka, Japan.
Technical Analysis
Trans Genic Inc.
―
MEDINET Co., Ltd.
―
TMS Co., Ltd.
―
Takara Bio Inc.
―
ReproCELL Inc.
―